Related Experiment Video
Updated: Jun 27, 2025
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Exploring the Link between Anticoagulation, Cognitive Impairment and Dementia in Atrial Fibrillation: A Systematic
Abhimanyu Agarwal1, Mohamed A Mostafa1, Muhammad Imtiaz Ahmad2
1Epidemiological Cardiology Research Center, Section on Cardiovascular Medicine, Department of Medicine, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA.
Insights
Oral anticoagulants may help prevent cognitive impairment and dementia in atrial fibrillation patients. Further research, including randomized controlled trials, is needed to confirm these findings for effective thromboprophylaxis.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Cognitive impairment and dementia risk in atrial fibrillation (AF) patients using oral anticoagulants (OACs) requires further investigation.
- Existing research on OACs' impact on cognitive health in AF is limited.
- This systematic review addresses the knowledge gap regarding OACs and cognitive decline in AF.
Purpose of the Study:
- To systematically review and synthesize evidence on the association between oral anticoagulant use and cognitive impairment or dementia in patients with atrial fibrillation.
- To evaluate the impact of different OACs, including direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs), on cognitive outcomes.
- To identify potential benefits of thromboprophylaxis in mitigating cognitive decline in AF patients.
Main Methods:
- Systematic literature search of SCOPUS and PubMed for English-language studies.
- Inclusion criteria focused on original research examining OACs and cognitive impairment/dementia in AF patients, excluding specific conditions like cancer or psychiatric illnesses.
- Data extraction and synthesis from 22 identified studies involving over 600,000 patients.
Main Results:
- Thirteen studies (n=597,744) indicated reduced cognitive impairment/dementia with thromboprophylaxis.
- Ten studies (n=284,636) showed lower cognitive impairment incidence with direct oral anticoagulants (DOACs).
- Three studies (n=61,991) suggested DOACs were associated with a lower dementia risk compared to vitamin K antagonists (VKAs), with better VKA control linked to lower dementia incidence.
Conclusions:
- Oral anticoagulants show potential in preventing cognitive impairment and dementia among atrial fibrillation patients.
- Observational data suggests a protective effect, particularly with DOACs.
- Further randomized controlled trials are essential to definitively establish the efficacy of anticoagulants in preserving cognitive function.
Abstract:
Background: The impact of oral anticoagulants (OACs) on cognitive impairment and dementia in patients with atrial fibrillation (AF) is not well characterized. This systematic review aims to address this knowledge gap. Methods: SCOPUS and PubMed searches were conducted to identify articles in the English language investigating the association between the use of OACs and cognitive impairment and dementia. We excluded non-original research studies and studies that did not report data on cognitive impairment or included patients who underwent open heart surgery or had psychiatric illnesses or cancer. Results: Out of 22 studies (n = 606,404 patients), 13 studies (n = 597,744 patients) reported a reduction in cognitive impairment/dementia in those undergoing thromboprophylaxis. Using direct oral anticoagulants (DOACs) was associated with a lower incidence of cognitive impairment in 10 studies (n = 284,636 patients). One study found that patients undergoing dual therapy (n = 6794 patients) had a greater incidence of cognitive impairment compared to those undergoing monotherapy (n = 9994 patients). Three studies (n = 61,991 patients) showed that AF patients on DOACs had a lower likelihood of dementia diagnosis than those on vitamin K antagonists (VKAs). Dementia incidence was lower when VKAs were under good control. Conclusions: The use of oral anticoagulants has the potential to prevent cognitive impairment and dementia in patients with AF. Since most of the published research on this subject is observational in nature, more randomized controlled trials are needed to fully understand the effect of anticoagulants on cognitive function.
Related Concept Videos
01:30Dementia
The progression of dementia is generally gradual....
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...